Literature DB >> 26768331

Screening of CD96 and ASXL1 in 11 patients with Opitz C or Bohring-Opitz syndromes.

Roser Urreizti1, Neus Roca-Ayats1, Judith Trepat1, Francisco Garcia-Garcia2,3, Alejandro Aleman3, Daniela Orteschi4, Giuseppe Marangi4, Giovanni Neri4, John M Opitz5, Joaquin Dopazo2,3, Bru Cormand1, Lluïsa Vilageliu1, Susana Balcells1, Daniel Grinberg1.   

Abstract

Opitz C trigonocephaly (or Opitz C syndrome, OTCS) and Bohring-Opitz syndrome (BOS or C-like syndrome) are two rare genetic disorders with phenotypic overlap. The genetic causes of these diseases are not understood. However, two genes have been associated with OTCS or BOS with dominantly inherited de novo mutations. Whereas CD96 has been related to OTCS (one case) and to BOS (one case), ASXL1 has been related to BOS only (several cases). In this study we analyze CD96 and ASXL1 in a group of 11 affected individuals, including 2 sibs, 10 of them were diagnosed with OTCS, and one had a BOS phenotype. Exome sequences were available on six patients with OTCS and three parent pairs. Thus, we could analyze the CD96 and ASXL1 sequences in these patients bioinformatically. Sanger sequencing of all exons of CD96 and ASXL1 was carried out in the remaining patients. Detailed scrutiny of the sequences and assessment of variants allowed us to exclude putative pathogenic and private mutations in all but one of the patients. In this patient (with BOS) we identified a de novo mutation in ASXL1 (c.2100dupT). By nature and location within the gene, this mutation resembles those previously described in other BOS patients and we conclude that it may be responsible for the condition. Our results indicate that in 10 of 11, the disease (OTCS or BOS) cannot be explained by small changes in CD96 or ASXL1. However, the cohort is too small to make generalizations about the genetic etiology of these diseases.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  ASXL1; Bohring-Opitz; CD96; Opitz C; developmental disease; molecular diagnosis; rare disease; trigonocephaly; whole exome sequencing

Mesh:

Substances:

Year:  2015        PMID: 26768331     DOI: 10.1002/ajmg.a.37418

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  4 in total

1.  A de novo truncating mutation in ASXL1 associated with segmental overgrowth.

Authors:  Stephanie Efthymiou; Vincenzo Salpietro; Erica Pironti; Maria Bonsignore; Valentina Ferrazzoli; Gabriella Di Rosa; Henry Houlden
Journal:  J Genet       Date:  2019-12       Impact factor: 1.166

2.  A De Novo FOXP1 Truncating Mutation in a Patient Originally Diagnosed as C Syndrome.

Authors:  Roser Urreizti; Sarah Damanti; Carla Esteve; Héctor Franco-Valls; Laura Castilla-Vallmanya; Raul Tonda; Bru Cormand; Lluïsa Vilageliu; John M Opitz; Giovanni Neri; Daniel Grinberg; Susana Balcells
Journal:  Sci Rep       Date:  2018-01-12       Impact factor: 4.379

3.  A De Novo Nonsense Mutation in MAGEL2 in a Patient Initially Diagnosed as Opitz-C: Similarities Between Schaaf-Yang and Opitz-C Syndromes.

Authors:  Roser Urreizti; Anna Maria Cueto-Gonzalez; Héctor Franco-Valls; Sílvia Mort-Farre; Neus Roca-Ayats; Julia Ponomarenko; Luca Cozzuto; Carlos Company; Mattia Bosio; Stephan Ossowski; Magda Montfort; Jochen Hecht; Eduardo F Tizzano; Bru Cormand; Lluïsa Vilageliu; John M Opitz; Giovanni Neri; Daniel Grinberg; Susana Balcells
Journal:  Sci Rep       Date:  2017-03-10       Impact factor: 4.379

4.  The ASXL1 mutation p.Gly646Trpfs*12 found in a Turkish boy with Bohring-Opitz Syndrome.

Authors:  Roser Urreizti; Semra Gürsoy; Laura Castilla-Vallmanya; Guillem Cunill; Raquel Rabionet; Derya Erçal; Daniel Grinberg; Susana Balcells
Journal:  Clin Case Rep       Date:  2018-06-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.